## GraÅ<sup>1</sup>/<sub>4</sub>yna Chodorowska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6250377/publications.pdf

Version: 2024-02-01

92 papers

1,363 citations

430874 18 h-index 395702 33 g-index

93 all docs 93
docs citations

93 times ranked 1963 citing authors

#	Article	IF	Citations
1	Cytokines and anticytokines in psoriasis. Clinica Chimica Acta, 2008, 394, 7-21.	1.1	144
2	Lipid Disturbances in Psoriasis: An Update. Mediators of Inflammation, 2010, 2010, 1-13.	3.0	98
3	Serum Levels of Selected Th17 and Th22 Cytokines in Psoriatic Patients. Disease Markers, 2013, 35, 625-631.	1.3	94
4	C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 180-183.	2.4	83
5	Cytokine network in psoriasis revisited. European Cytokine Network, 2011, 22, 160-168.	2.0	73
6	Social support and adaptation to the disease in men and women with psoriasis. Archives of Dermatological Research, 2012, 304, 421-432.	1.9	63
7	Cardiovascular aspects of psoriasis: an updated review. International Journal of Dermatology, 2013, 52, 153-162.	1.0	52
8	Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology, 2011, 50, 746-755.	1.9	51
9	The Role of Vitamin D in Non-Scarring Alopecia. International Journal of Molecular Sciences, 2017, 18, 2653.	4.1	36
10	Interleukin-18 Levels in the Plasma of Psoriatic Patients Correlate with the Extent of Skin Lesions and the PASI Score. Acta Dermato-Venereologica, 2003, 83, 262-263.	1.3	32
11	Metabolic syndrome in vitiligo. Dermatologic Therapy, 2012, 25, S41-S43.	1.7	32
12	Biochemical markers of psoriasis as a metabolic disease. Folia Histochemica Et Cytobiologica, 2012, 50, 155-170.	1.5	30
13	Psoriasis and serum lipid abnormalities. Dermatologic Therapy, 2010, 23, 160-173.	1.7	26
14	Interleukin-22 and Its Correlation with Disease Activity in Plaque Psoriasis. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 103-108.	2.3	26
15	Plasma concentrations of IFN-? and TNF-?: in psoriatic patients before and after local treatment with dithranol ointment. Journal of the European Academy of Dermatology and Venereology, 1998, 10, 147-151.	2.4	25
16	Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. International Journal of Dermatology, 2009, 48, 379-387.	1.0	25
17	The Assessment of Selected Bone and Cartilage Biomarkers in Psoriatic Patients from Poland. Mediators of Inflammation, 2015, 2015, 1-8.	3.0	22
18	Rational for statin use in psoriatic patients. Archives of Dermatological Research, 2013, 305, 467-472.	1.9	21

#	Article	IF	Citations
19	Genes and structure of selected cytokines involved in pathogenesis of psoriasis Folia Histochemica Et Cytobiologica, 2008, 46, 11-21.	1.5	18
20	Cutaneous larva migrans syndrome: a. Postepy Dermatologii I Alergologii, 2013, 2, 119-121.	0.9	17
21	Suppressed Programmed Death 1 Expression on CD4 <sup>+</sup> and CD8 <sup>+</sup> T Cells in Psoriatic Patients. Mediators of Inflammation, 2017, 2017, 1-8.	3.0	17
22	IL-17A in the Psoriatic Patients' Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity. Mediators of Inflammation, 2020, 2020, 1-9.	3.0	16
23	Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis. Postepy Dermatologii I Alergologii, 2018, 35, 344-350.	0.9	15
24	Results of Nailfold Capillaroscopy in Patients with Normal-Tension Glaucoma. Current Eye Research, 2018, 43, 747-753.	1.5	14
25	Plasma concentrations of IFN- $\hat{l}^3$ and TNF- $\hat{l}^{\pm}$ in psoriatic patients before and after local treatment with dithranol ointment. Journal of the European Academy of Dermatology and Venereology, 1998, 10, 147-151.	2.4	13
26	Increased serum level of Nâ€ŧerminal Proâ€Bâ€ŧype natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1010-1014.	2.4	13
27	Risk Factors for Normal and High-Tension Glaucoma in Poland in Connection with Polymorphisms of the Endothelial Nitric Oxide Synthase Gene. PLoS ONE, 2016, 11, e0147540.	2.5	13
28	IFAP syndrome with severe cutaneous, neurologic and skeletal manifestations due to a novel MBTPS2 mutation in a Polish patient. European Journal of Dermatology, 2012, 22, 467-472.	0.6	13
29	Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Przeglad Dermatologiczny, 2020, 107, 92-108.	0.1	12
30	Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. Polish Archives of Internal Medicine, 2017, 127, 815-822.	0.4	11
31	Videocapillaroscopic Alterations in Alopecia Areata. BioMed Research International, 2013, 2013, 1-7.	1.9	10
32	Serum pancreatic lipase [EC 3.1.1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. Journal of Molecular Catalysis B: Enzymatic, 2006, 40, 144-154.	1.8	9
33	THERAPEUTIC HOTLINE: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide. Dermatologic Therapy, 2010, 23, 676-681.	1.7	9
34	Diffuse cutaneous bullous mastocytosis in a newborn. Dermatologic Therapy, 2013, 26, 176-179.	1.7	9
35	Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring. Przeglad Dermatologiczny, 2017, 5, 483-498.	0.1	9
36	Trichophyton mentagrophytes-associated Majocchi's granuloma treated with cryotherapy. Folia Histochemica Et Cytobiologica, 2012, 50, 486-489.	1.5	9

#	Article	IF	Citations
37	Localized scleroderma (morphea). Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przeglad Dermatologiczny, 2019, 106, 333-353.	0.1	8
38	Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2. Przeglad Dermatologiczny, 2020, 107, 110-137.	0.1	8
39	Assessment of Selected Matrix Metalloproteinases (MMPs) and Correlation with Cytokines in Psoriatic Patients. Mediators of Inflammation, 2021, 2021, 1-8.	3.0	8
40	The expression of selected molecular markers of immune tolerance in psoriatic patients. Advances in Clinical and Experimental Medicine, 2018, 27, 721-725.	1.4	8
41	Traditional Chinese medicine herbs — are they safe for psoriatic patients?. Folia Histochemica Et Cytobiologica, 2011, 49, 201-205.	1.5	8
42	Future diagnosis, today's treatment - cardiomyopathy in the course of psoriasis: a case report. Dermatologic Therapy, 2013, 26, 489-492.	1.7	7
43	Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I: Mild psoriasis. Przeglad Dermatologiczny, 2018, 105, 225-243.	0.1	7
44	Clinical usefulness of high-frequency ultrasonography in the monitoring of basal cell carcinoma treatment effects. Postepy Dermatologii I Alergologii, 2020, 37, 364-370.	0.9	7
45	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells, 2021, 10, 411.	4.1	7
46	Osteopontin Serum Concentration and Metabolic Syndrome in Male Psoriatic Patients. Journal of Clinical Medicine, 2021, 10, 755.	2.4	7
47	Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities. Advances in Clinical and Experimental Medicine, 2020, 29, 79-84.	1.4	7
48	Bullous pyoderma gangrenosum associated with pancytopenia of unknown origin. Postepy Dermatologii I Alergologii, 2014, 4, 272-276.	0.9	6
49	Cardiovascular disease in psoriatic postâ€menopausal women. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1231-1234.	2.4	6
50	Serum concentration of osteopontin and interleukin 17 in psoriatic patients. Advances in Clinical and Experimental Medicine, 2020, 29, 203-208.	1.4	6
51	Somatic and non-somatic problems connected with psoriasis in pregnancy. Ginekologia Polska, 2013, 84, 211-3.	0.7	6
52	Development of squamous cell carcinoma within lesions of cutaneous lichen planus. European Journal of Dermatology, 2007, 17, 447-8.	0.6	6
53	The â€308 Promoter Polymorphism in the Tumour Necrosis Factor Gene in Patients with Lichen Planus. Acta Dermato-Venereologica, 2005, 85, 400-403.	1.3	5
54	Psoriasis and unreported excessive alcohol intake $\hat{a} \in \text{``a simple screening approach. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1261-1268.}$	2.4	5

#	Article	IF	CITATIONS
55	Psoriatic erythroderma coexisting with erythema multiforme-like lesions induced by retinoids or retinoids combined with an antibiotic: case report. Dermatologic Therapy, 2011, 24, 587-590.	1.7	5
56	Evaluation of Endostatin and EGF Serum Levels in Patients with Gastric Cancer. Polski Przeglad Chirurgiczny, 2011, 83, 42-7.	0.4	5
57	Ectrodactyly-ectodermal dysplasia-clefting syndrome with unusual cutaneous vitiligoid and psoriasiform lesions due to a novel single point TP63 gene mutation. Postepy Dermatologii I Alergologii, 2019, 36, 358-364.	0.9	5
58	The plasma level of sICAM-1 in the chosen inflammatory dermatoses. Journal of the European Academy of Dermatology and Venereology, 1997, 8, 29-33.	2.4	4
59	Plasma Interleukin-18 and Dendritic Cells in Males with Psoriasis Vulgaris. Mediators of Inflammation, 2007, 2007, 1-7.	3.0	4
60	Treatment of psoriasis vulgaris: guidelines of experts of the Polish Dermatological Society. Part II: moderate to severe psoriasis. Przeglad Dermatologiczny, 2014, 6, 455-472.	0.1	4
61	Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment. Przeglad Dermatologiczny, 2017, 104, 583-596.	0.1	4
62	Psoriasis vulgaris and digestive system disorders: is there a linkage?. Folia Histochemica Et Cytobiologica, 2010, 47, 517-24.	1.5	4
63	Melanoma and other malignant skin cancers in psoriatic patients treated with phototherapy. Role of the p16 protein in psoriasis. Folia Histochemica Et Cytobiologica, 2012, 50, 491-496.	1.5	4
64	Interleukin-2 and its soluble receptor in selected drug-induced cutaneous reactions. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina, 2003, 58, 7-13.	0.0	4
65	Deleterious effects of traditional Chinese medicine preparations on the course of psoriasisa case report. Annals of Agricultural and Environmental Medicine, 2013, 20, 816-8.	1.0	4
66	Acute respiratory distress syndrome (ARDS) complicating influenza A/H1N1v infection-a clinical approach. Annals of Agricultural and Environmental Medicine, 2013, 20, 820-2.	1.0	4
67	Long-term observation of a case of cutaneous blastomycosis in Poland treated with fluconazole. Mycoses, 1996, 39, 283-287.	4.0	3
68	Immune system disturbances in Clouston syndrome. International Journal of Dermatology, 2016, 55, e241-9.	1.0	3
69	Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients. Postepy Dermatologii I Alergologii, 2019, 36, 167-172.	0.9	3
70	Drug-induced hyperergic vasculitisactivity of selected cytokines and acute phase proteins in plasma. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina, 2003, 58, 43-7.	0.0	3
71	Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Associated with Anaemia and Thrombocytopaenia. Acta Dermato-Venereologica, 2009, 89, 646-648.	1.3	2
72	Candida parapsilosis infection following the electrosurgery procedure. Dermatologic Therapy, 2011, 24, 131-133.	1.7	2

#	Article	IF	Citations
73	Metabolic syndrome in psoriasis. Advances in Dermatology and Allergology, 2012, 5, 356-362.	1.0	2
74	Eruption of palmoplantar pustular psoriasis in patient treated with anti-androgen therapy for prostate cancer and aggravation of lesions after statin treatment. Open Medicine (Poland), 2014, 9, 657-662.	1.3	2
75	Analysis of serum chemerin concentrations in psoriatic patients in relation to metabolic abnormalities. Postepy Dermatologii I Alergologii, 2019, 36, 531-537.	0.9	2
76	Plasma activity of interleukin-10 in drug-induced cutaneous reactions. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina, 2003, 58, 317-21.	0.0	2
77	Sonographic assessment of the liver in children with psoriasis. Journal of Clinical Ultrasound, 2004, 32, 344-347.	0.8	1
78	Skin lesions in a 16-month-old toddler with impaired zinc absorption. Advances in Medical Sciences, 2011, 56, 369-372.	2.1	1
79	Vulvo-vaginal-gingival syndrome – a. Przeglad Dermatologiczny, 2014, 4, 299-303.	0.1	1
80	The role of vitamin D in alopecia areata. Przeglad Dermatologiczny, 2016, 2, 185-188.	0.1	1
81	Activity of Tumor Necrosis Factor-alpha (TNF-alpha) and its soluble type I receptor (p55TNF-R) in some drug-induced cutaneous reactions. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina, 2003, 58, 50-6.	0.0	1
82	IL-6 and FAS (CD95) serum level in patients suffering from psoriasis and in relation to the lymphocyte subpopulations. Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina, 2004, 59, 500-4.	0.0	1
83	The percentage of T helper lymphocytes CD4+ bearing interleukin-6 receptors is lower in the blood of patients with acute psoriasis triggered by infection. Journal of the European Academy of Dermatology and Venereology, 2004, 18, 379-381.	2.4	O
84	Psoriasis and menopause Part I. Impact of psoriasis on quality of life in women in peri- and postmenopausal age. Przeglad Menopauzalny, 2012, 5, 388-391.	1.3	0
85	Psoriasis and osteoporosis. Przeglad Menopauzalny, 2013, 2, 159-162.	1.3	O
86	Actinic keratosis – state of art. Statement of experts of Polish Dermatological Society. Przeglad Dermatologiczny, 2014, 2, 156-167.	0.1	0
87	Mucous membrane pemphigoid as a cause of acute dysphagia – an endoscopic study. Przeglad Gastroenterologiczny, 2015, 4, 247-249.	0.7	O
88	Capillaroscopic patterns in patients with systemic sclerosis, psoriasis and alopecia and their correlations with serum concentrations of several angiogenic markers. Zdrowie Publiczne, 2015, 125, 49-54.	0.1	0
89	Application of antimalarial medications in the treatment of skin diseases. Przeglad Dermatologiczny, 2016, 4, 316-322.	0.1	O
90	Skin changes in chronic kidney disease. Przeglad Dermatologiczny, 2017, 2, 142-153.	0.1	0

#	Article	IF	CITATIONS
91	Z życia PTD Stanowisko Polskiego Towarzystwa Dermatologicznego w sprawie wykonywania zabiegów z zakresu medycyny estetycznej oraz diagnostyki i leczenia chorób dermatologicznych przez osoby nieposiadajÄ…ce wyksztaÂ,cenia lekarskiego. Przeglad Dermatologiczny, 2017, 5, 579-582.	0.1	O
92	The Genetic Variants of NOTCH3 (6746T>C) and PSMA6 (-8C>G) as Possible Risk Factors of Psoriasis Development. Life, 2021, 11, 887.	2.4	0